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Abstract
Background: Intrapancreatic accessory spleen (IPAS) is an uncommon finding of pancreatic mass. Differential
diagnosis with pancreatic tumor, especially with non-functional neuroendocrine tumor (NF-NET), may be very hard
and sometimes it entails unnecessary surgery. A combination of CT scan, MRI, and nuclear medicine can confirm
the diagnosis of IPAS. 68-Ga-Dotatoc PET/CT is the gold standard in NET diagnosis and it can allow to distinguish
between IPAS and NET.
Case presentation: A 69-year-old man was admitted to our hospital for an incidental nodule in the tail of the
pancreas with focal uptake of 68-Ga-dotatate at PET/CT. NET was suspected and open distal splenopancreatectomy
was performed. Pathologic examination revealed an IPAS.
Conclusion: This is the second IPAS case in which a positive 68Ga-Dotatoc uptake led to a false diagnosis of
pancreatic NET. Here is a proposal of a literature review.
Keywords: Intrapancreatic accessory spleen, False positive to 68Ga-Dotatoc, Neuroendocrine tumor, Pancreatic
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Background
Accessory spleen is a congenital abnormality consisting
of normal splenic tissue in ectopic sites. It arises as a
failure of fusion between some of the multiple buds of
splenic tissue in the dorsal mesogastrium during
embryologic life. This ectopic tissue can be found, in
order of frequency in the following: splenic hilum (80%),
pancreatic tail (20%), stomach, bowel, and genitals [1, 2].
In autoptic studies, the accessory spleen has an inci-
dence of 10% and IPAS of 2% [3], but clinical incidence,
despite rare, is growing probably related to the improve-
ment of diagnostic imaging accuracy. Rarely a specific
abdominal pain or idiopathic thrombocytopenic purpura
(not responsive to splenectomy) could be present in
patients with IPAS [4]. Because asymptomatic, IPAS is
almost always found incidentally as an undefined
pancreatic mass similar to NETs [5]. The frequency of
functional pancreatic NETs (F-P-NETs), similar to that
of non-functional pancreatic NETs (NF-P-NETs), is
probably increasing [5] due to the widespread use of
high-quality imaging techniques [6]. Recent studies have
shown imaging with 68-Ga-labeled somatostatin analogs
with PET/CT to be highly sensitive and specific for P-
NETs [7]. We are illustrating a 69-year-old man with a
mass in the tail of the pancreas found during his follow-
up for previous sigmoid colon adenocarcinoma. Because
of a positive result at 68-Ga-Dotatoc PET/CT and volu-
metric increasing of mass during follow-up, a P-NET
was suspected.
Case presentation
A 69-year-old man with a past medical history signifi-
cant for hypertension and sigmoid adenocarcinoma
(UICC 2012: pT4 pN2 M0) underwent sigmoid colec-
tomy and adjuvant chemotherapy (2015). No pancreatic
mass was described at the computed tomography (CT)
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images performed after colectomy. During the follow-
up, a magnetic resonance imaging (MRI) showed a 1.5-
cm nodule of the pancreatic tail, non-homogeneous,
hyperintense on T2-weighted and hypointense on T1-
weighted sequence, and a focal lesion inside hyperin-
tense on T1. Endoscopic ultrasonography (EUS) revealed
a 1.5-cm anechoic nodule, with two hyperechoic foci
ascribable to calcifications. The needle biopsy (EUS-
FNA) was not performed due to difficulties of
endoscopic examination (the nodule was too far from
the duodenal wall). 18-Fluorodeoxyglucose positron
emission tomography ([18-F] FDG-PET) did not show
FDG uptake.
Follow-up indication was given. After 8 months, this
lesion showed a volumetric increase (2 cm) both at com-
puted tomography (CT) and MRI (Fig. 1 and Fig. 2) with-
out pathological uptake at FDG-PET. Tumoral markers
(CA 19.9, CEA, alpha-fetoprotein) were negative. A 68-
Ga-Dotatoc PET/CT, more sensitive and specific for neu-
roendocrine tumor (NET), showed a focal area of uptake
Fig. 1 Incidental mass in the tail of the pancreas (arrow). CT revealed a mass well delimited with homogeneous contrast enhancement. a Venous
and b arterial phase axial CT images
Fig. 2 MRI confirmed a 2-cm nodule of the tail of the pancreas hypointense on T1 (a) and hyperintense on T2 (b)-weighted sequence with a
focal lesion inside hyperintense on T1. Diffusion-weighted MR imaging shows a high restriction (c) and hypointense in T1 fat sat sequence (d)
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(Fig. 3), but neuroendocrine markers (gastrin, chromogra-
nin A, calcitonin, 5-hydroxytryptophan) were negative.
Given the suspicion of NF-P-NET and close contact to
splenic vessels, the patient underwent open distal spleno-
pancreatectomy (Fig. 4) with an unremarkable postopera-
tive course.
Definitive histologic examination revealed an intrapan-
creatic accessory spleen, with multiseptated epidermoid
cyst (Fig. 5).
Discussion
In the English literature, there are, up to date, only 144
articles of which 115 are case reports concerning diag-
nosis and treatment of IPAS. From this data review, it
was observed that most patients with IPAS underwent
surgery without a preoperative definitive diagnosis and
that IPAS was often put in differential diagnosis with
NET or rarely with adenocarcinoma or metastatic tu-
mors [8]. In Table 1, we report the literature results of
diagnostic procedures performed, when clearly specified,
in patients with IPAS [9–31]. Despite the high diagnostic
accuracy of morphological and scintigraphic exams,
IPAS was often unidentified and unnecessary surgery
was performed in 66.6% of patients. False-negative
results have been reported also after endoscopic
ultrasonography-guided fine needle aspiration biopsy
(EUS-FNA) and after Tc-99m heat-damaged red blood
cell (HDRBD) scintigraphy.
The context is usually a CT/MRI incidental diagnosis
of a nodule localized in the pancreatic tail, between 1
and 3 cm, well-delimited, homogeneous, and hypervas-
cular: IPAS should be suspected and more examinations
required.
Tumoral and neuroendocrine markers have a limited
role in the differential diagnosis. In pancreatic carcin-
oma, the most important tumoral markers are CA 19.9,
CEA, CA125 (sensitivity of 81.3%, 39%, and 56.4%; spe-
cificity of 75.9%, 91.4%, and 77.6% respectively) [32, 33].
Fig. 3 The PET image shows an indeterminate pancreatic tail nodule with enhanced uptake of 68-Ga-dotatate at PET-CT fusion image (false positive)
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Approximately 50% of NET are non-functional tumors;
in functional ones, neuroendocrine marker sensitivity is
about 80% while specificity is much lower [34]. However,
false-positive cases consisting of IPAS with increased
tumoral and neuroendocrine markers have been re-
ported [10, 13]. Therefore, serological markers are not
useful in the differential diagnosis between IPAS and
NET or pancreatic carcinoma, as in our case.
For these reasons, a careful evaluation of the radio-
logical images is very important.
At CT, IPAS shows attenuation and enhancement
similar to the spleen in all phases, more than pancreatic
parenchyma. Pancreatic tumors, instead, show a greater
attenuation in the arterial phase and less in the venous
phase [13, 19].
At MRI, IPAS often shows a low signal intensity in T1
and high intensity in T2 if compared to pancreatic
parenchyma; moreover, intratumoral hemorrhage and
necrosis are absent in IPAS [19]. The key to suspect
IPAS at MRI is detecting the signal intensity of the mass
similar to the spleen in all sequences [13]. On the other
hand, Kim et al. demonstrated that sometimes IPAS
signal intensity is slightly brighter than the spleen on the
T2-weighted images, and this finding is due to the
higher white-to-red pulp ratio of IPAS [13]. Recently,
Jang et al. [23], in a retrospective study, have considered
diffusion-weighted MRI (RMDW) value in the differen-
tial diagnosis between IPAS and solid pancreatic tumors
of less than 3 cm showing a 90% sensitivity and specifi-
city. An Italian group in 2005 correctly diagnosed IPAS
(without surgery), observing the same pattern of the
spleen at CT and at MRI with reticuloendothelial system-
specific contrast medium (ferucarbotran), confirmed by
mass stability after 16months of follow-up [25].
Nuclear medicine has surely a role in IPAS diagnosis.
Octreoscan and 68-Ga-PET/CT have been considered
reliable in case of NET, while Tc-99m heat-damaged red
blood cell (HDRBD) is specific for splenic tissue.
According to variable expression NET somatostatin
receptors (high or low), it is possible unfortunately uni-
dentify these tumors only with radiolabelled somato-
statin analog agent [35]. Furthermore, there are non-
tumoral processes (autoimmune diseases, pneumonias,
etc.) and some tissues (spleen, kidney, thyroid, liver) that
can have avidity for scintigraphy contrast, causing false
positives. Octreoscan sensitivity and specificity for NET
is about 80% while 68-Ga-Dotatoc seems to be superior
(sensitivity and specificity range 80–100%) [36]. There-
fore, for NET diagnosis, the actual gold standard is 68-
Ga-PET-CT. To date, in the English literature, there is
only one IPAS case in which a positive 68-Ga-PET/Tc
uptake led to a wrong diagnosis of pancreatic NET [1]
probably due to physiological radioisotope uptake in
splenic tissue (false positive) [30, 37, 38]. We present the
second case of IPAS positive at 68-Ga-PET/CT. About
68-Ga-PET-CT sensitivity and specificity, it should be
considered that the splenic tissue uptake of 68-Ga-
Dotatoc is highly variable [39, 40]. The accuracy seems
significantly higher for NET restaging than diagnosis [41]
and then a histological confirmation for final diagnosis
could be still considered [42]. Therefore, the diagnostic
reliability of the 68-Ga-PET/TC in terms of differential
diagnosis between NET and IPAS is still debated.
Technetium 99-m HDRBD scintigraphy is a specific
technique for splenic tissue identification because of the
physiological radioisotope uptake: focal uptake in the
pancreatic tail suggests the presence of splenic intrapan-
creatic tissue [17]. Method limits are inferior spatial
Fig. 4 Gross pathologic findings of IPAS: S the main spleen; P the tail of the pancreas. The arrow shows a reddish nodule with epidermoid cyst
surrounded by pancreatic parenchyma
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resolution compared to other cross-sectional imaging
modalities and need for a certain quantity of spleen
functional ectopic tissue to visualize marked cells (cutoff
dimension of 1.1 cm according to Kim et al.) [13].
Consequently, Tc-99m HDRBC scintigraphy is an exam
that can be used as a confirmatory test for IPAS (positive
predictive value) but false-negative results have been
reported [19, 23, 31] (Table 1). In our case, it was not
performed because 68-Ga-PET/TC positive result was
considered conclusive.
EUS-FNA, despite a certain rate of complications and
false negatives, gives significant morphological and cyto-
logical informations. Schreiner et al. in 2008 first de-
scribed a series of 3 IPAS identified by EUS, suggesting
the need for a histologic diagnosis (FNA biopsy) in case
of unconclusive imaging [14]. Cytological features for
Fig. 5 Microscopic findings (hematoxylin and eosin staining). a, b It is possible to observe the interface between pancreatic parenchyma (red
arrow) and accessory spleen with epidermoid cyst (yellow arrow) (H&E, × 4). c Histological picture of intrapancreatic splenic parenchyma with
adjacent normal pancreas (H&E, × 40). d Multiseptated intrasplenic epithelial cyst, with multilayered squamous epithelium (H&E, × 40)
Table 1 Literature review of 87 cases of IPAS confirmed by postoperative histological examination or by follow-up: diagnostic
hypothesis and related surgical treatment [9–31]. Fifty-eight cases treated with surgery (66.6%)
Patients,
n
Diagnostic hypothesis Unnecessary surgery
IPAS U NET Other Misleading, n (%) n %
CT scan 57 13 16 24 4 44 (77.1) 31 54.3
MRI 60 32 10 11 7 28 (46.6) 40 66.6
EUS 30 3 14 12 1 27 (90) 15 50
EUS-FNA 20 15 2 3 0 5 (25) 8 40
Octreoscan 9 0 7 2 0 2 (22.2) 7 77.7
HDRBD 10 6 0 4 0 4 (40) 6 60
U unclear
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differential diagnosis of IPAS from other pancreatic nod-
ules were described by Tatsas et al. [22]. In case of IPAS,
there is a population of inflammatory cells (principally
lymphocytes, but also monocytes, neutrophils, eosino-
phils) while immunocytochemical staining of CD8
specifically highlights endothelial cells of the thin-walled
blood vessels [22]. EUS-FNA biopsy has a high (80–
90%) sensitivity and specificity for pancreatic neuroen-
docrine tumors although its accuracy for such tumors is
considered lower than the accuracy for pancreatic
adenocarcinoma [21]. Although false-positive results
have been reported [11, 16, 31], the rate of unnecessary
surgery after EUS-FNA biopsy is lower (40%) compared
with other morphological exams (Table 1). There is also
the possibility of performing a contrast-enhancement
EUS (CEUS) with intravenous contrast (Levovist or
Sonazoid) without FNA: it may become the gold stand-
ard in IPAS diagnosis [43].
Finally, there is another method proposed for IPAS
diagnosis: confocal laser endomicroscopy (CLE) [24].
CLE is an endoscopic technique which allows to obtain
the mucosal images with a magnification of about ×
1000. This technique allows to identify cellular and sub-
cellular microstructures and an in vivo histological diag-
nosis (optical virtual biopsy). The use of needle-based
probe CLE prior to EUS-FNA in the diagnosis of pan-
creatic masses may increase diagnostic accuracy [24].
To date, there are no guidelines but recommended
diagnostic algorithms to suspect and diagnose IPAS have
been proposed by Spencer et al., Li et al., and Baugh et
al. [19, 31, 44].
Conclusion
In the differential diagnosis of solid nodules in the
pancreatic tail, IPAS should always be considered.
Besides increasing clinical incidence due to the improve-
ment of imaging quality, it remains a non-neoplastic
lesion with no surgical indication. IPAS should be sus-
pected in the presence of some features: incidentally
asymptomatic lesion, localization in the tail of the pan-
creas, dimension between 1 and 3 cm, well-delimited
homogeneous and hypervascular nodule, similar attenu-
ation to the spleen on CT and MRI, negativity of neuro-
endocrine, and tumoral markers. A combination of CT,
MRI, nuclear medicine examinations, and EUS-FNA
biopsy could be necessary for a diagnosis of IPAS
because none of them are individually conclusive. False
positives or false negatives are possible, as in our clinical
case with 68-Ga-Dotatoc PET/CT false positive.
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